Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)

PURPOSE: In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473). METHODS: We enrolled patients with metastatic RCC with no prior checkpoint inhibitor exposure. All pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: McKay, Rana R., McGregor, Bradley A., Xie, Wanling, Braun, David A., Wei, Xiao, Kyriakopoulos, Christos E., Zakharia, Yousef, Maughan, Benjamin L., Rose, Tracy L., Stadler, Walter M., McDermott, David F., Harshman, Lauren C., Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768333/
https://ncbi.nlm.nih.gov/pubmed/33108238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02295
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados